Evidence map›Paper›PMID 37063416›Full record

ArticleInternational journal of biological sciences2023

Cardiovascular-related proteomic changes in ECFCs exposed to the serum of COVID-19 patients.

Lucía Beltrán-Camacho, Santosh D Bhosale, Daniel Sánchez-Morillo, Ismael Sánchez-Gomar, Marta Rojas-Torres, Sara Eslava-Alcón, Mario Martínez-Torija, Mª Angeles Ruiz de Infante, Mª Dolores Nieto-Martín, Manuel A Rodríguez-Iglesias and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Lucía Beltrán-CamachoBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Santosh D BhosaleDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark.
Daniel Sánchez-MorilloBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Ismael Sánchez-GomarBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Marta Rojas-TorresBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Sara Eslava-AlcónBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Mario Martínez-TorijaDepartment of Nursing, National Paraplegic Hospital, Toledo, Spain.
Mª Angeles Ruiz de InfanteOccupational Health Service, National Paraplegic Hospital, SESCAM, 45071, Toledo, Spain.
Mª Dolores Nieto-MartínInternal Medicine Department, University Hospital Virgen del Rocío, Seville, Spain.
Manuel A Rodríguez-IglesiasBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Juan A MorenoCell Biology, Physiology and Immunology Department, Agrifood Campus of International Excellence (ceiA3), University of Cordoba, 14014, Córdoba, Spain.
Esther BerrocosoBiomedical Research and Innovation Institute of Cadiz (INiBICA), 11002 Cadiz, Spain.
Martin R LarsenDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark.
Rafael Moreno-LunaLaboratory of Neuroinflammation, National Paraplegic Hospital, 45071 Toledo, Spain.
Mª Carmen Durán-RuizBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002 Cadiz, Spain.
Biomedical Research and Innovation Institute of Cadiz · ESHospital Nacional de Parapléjicos · ESUniversidad de Cádiz · ESUniversity of Southern Denmark · DKHospital Universitario Virgen del Rocío · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection significantly affects the cardiovascular system, causing vascular damage and thromboembolic events in critical patients. Endothelial dysfunction represents one of the first steps in response to COVID-19 that might lead to cardiovascular complications and long-term sequelae. However, despite the enormous efforts in the last two years, the molecular mechanisms involved in such processes remain poorly understood. Herein, we analyzed the protein changes taking place in endothelial colony forming cells (ECFCs) after the incubation with the serum from individuals infected with COVID-19, whether asymptomatic or critical patients, by application of a label free-quantitative proteomics approach. Specifically, ECFCs from healthy individuals were incubated

Indexed as

Cardiovascular SystemCOVID-19CalpainCells, CulturedHumansImmunoglobulin GMembrane ProteinsProteomicsSARS-CoV-2CalpainCapn5 protein, humanImmunoglobulin GMembrane ProteinsSURF4 protein, humanautophagycardiovascular diseasesCOVID-19ECFCsendothelial dysfunctionmass spectrometryproteomicsRNA metabolismViral infection

Identifiers

PMID37063416
PMCPMC10092762
OpenAlexW4324009863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.